Genetic modifiers of CHEK2*1100delC-associated breast cancer risk
Taru Muranen(Karolinska Institutet), Irene L. Andrulis(University of Toronto), Minouk J. Schoemaker(Institute of Cancer Research), Angela Cox, Hiltrud Brauch(German Cancer Research Center), Frederik Marmé(Heidelberg University), Matthieu Moisse(VIB-KU Leuven Center for Brain & Disease Research), Natalia Bogdanova(Medizinische Hochschule Hannover), Julian Peto(London School of Hygiene & Tropical Medicine), Peter A. Fasching(Universitätsklinikum Erlangen), Jingmei Li(Genome Institute of Singapore), Annika Lindblom(Karolinska University Hospital), Simon S. Cross(University of Sheffield), Thilo Dörk(Hannover Re (Germany)), Jonine D. Figueroa, Anthony J. Swerdlow(Institute of Cancer Research), Dario Greco(University of Helsinki), Alison M. Dunning(University of Cambridge), Ian Tomlinson(University of Oxford), Kristiina Aittomäki(Helsinki University Hospital), Sofia Khan(University of Helsinki), Per Hall(Karolinska Institutet), Antoinette Hollestelle(Erasmus MC Cancer Institute), Э. К. Хуснутдинова(Russian Academy of Sciences), Robert Luben(University of Cambridge), Carl Blomqvist(University of Helsinki), Elinor J. Sawyer(King's College London), Peter Hillemans(Medizinische Hochschule Hannover), John W.M. Martens(Erasmus MC), Ute Hamann(German Cancer Research Center), Mitul Shah(University of Cambridge), Stig E. Bojesen(University of Copenhagen), Tjoung‐Won Park‐Simon(Medizinische Hochschule Hannover), Montserrat García‐Closas(Institute of Cancer Research), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Børge G. Nordestgaard(Gentofte Hospital), Janet E. Olson(Cornell University), Rita K. Schmutzler(Weatherford College), Barbara Burwinkel(German Cancer Research Center), Vessela Kristensen(University of Oslo), Matthias W. Beckmann, Frans B.L. Hogervorst(The Netherlands Cancer Institute), Paul D.P. Pharoah(University of Cambridge), Anne‐Lise Børresen‐Dale(Oslo University Hospital), Senno Verhoef(The Netherlands Cancer Institute), Fergus J. Couch(Mayo Clinic), Alfons Meindl(Helmholtz Zentrum München), Isabel dos‐Santos‐Silva(London School of Hygiene & Tropical Medicine), Sara Margolin(University of Copenhagen), Marina Bermisheva(Russian Academy of Sciences)
Cited by 87
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k